Cite
Axillary lymph node dissection versus radiotherapy in breast cancer with positive sentinel nodes after neoadjuvant therapy (ADARNAT trial).
MLA
Garcia-Tejedor, Amparo, et al. “Axillary Lymph Node Dissection versus Radiotherapy in Breast Cancer with Positive Sentinel Nodes after Neoadjuvant Therapy (ADARNAT Trial).” Frontiers in Oncology, Aug. 2023, pp. 1–11. EBSCOhost, https://doi.org/10.3389/fonc.2023.1184021.
APA
Garcia-Tejedor, A., Ortega-Exposito, C., Salinas, S., Luzardo-González, A., Falo, C., Martinez-Pérez, E., Pérez-Montero, H., Soler-Monsó, M. T., Bajen, M.-T., Benitez, A., Ortega, R., Petit, A., Guma, A., Campos, M., Plà, M. J., Pernas, S., Peñafiel, J., Yeste, C., Gil-Gil, M., & Guedea, F. (2023). Axillary lymph node dissection versus radiotherapy in breast cancer with positive sentinel nodes after neoadjuvant therapy (ADARNAT trial). Frontiers in Oncology, 1–11. https://doi.org/10.3389/fonc.2023.1184021
Chicago
Garcia-Tejedor, Amparo, Carlos Ortega-Exposito, Sira Salinas, Ana Luzardo-González, Catalina Falo, Evelyn Martinez-Pérez, Héctor Pérez-Montero, et al. 2023. “Axillary Lymph Node Dissection versus Radiotherapy in Breast Cancer with Positive Sentinel Nodes after Neoadjuvant Therapy (ADARNAT Trial).” Frontiers in Oncology, August, 1–11. doi:10.3389/fonc.2023.1184021.